Trial Profile
Interventional, Randomized, Double-blind, Active-controlled Study of the Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 22 Jul 2020
Price :
$35
*
At a glance
- Drugs LU AF-35700 (Primary) ; Olanzapine; Risperidone
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms Anew
- Sponsors Lundbeck A/S
- 22 Jul 2020 This trial has been completed in UK (Global End Date: 05 Feb 2019), according to European Clinical Trials Database record.
- 26 Feb 2019 This trial has been completed in Bulgaria, according to European Clinical Trials Database.
- 08 Feb 2019 Status changed from active, no longer recruiting to discontinued.